SEC Form 4 · accession 0001628280-26-057759
Pacira BioSciences, Inc. · PCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Slonin
Officer — Chief Medical Officer
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 5:21 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001396814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 17, 2026 | S | 3,040 | $23.23 | D | 216,384 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.
- F2Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.